+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in renal cell carcinoma



Expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in renal cell carcinoma



Zhonghua Yi Xue Za Zhi 91(44): 3127-3130



To explore the expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) in renal cell carcinoma. The expression of PD-ECGF in 76 specimens of renal cell carcinoma from June 2002 to December 2006 was examined by EnVision immunohistochemistry. The correlation of the expression of PD-ECGF with the clinicopathological characteristics and prognosis in renal cell carcinoma patients were analyzed. Among 76 renal cell carcinoma patients, 41 patients had a high-level expression of PD-ECGF while another 35 patients a low-level expression. The expression of PD-ECGF was positively correlated with tumor stage and histological grade. The 5-year overall survival rate was significant lower in the patients with a high-level expression of PD-ECGF (60.98% vs 94.29%, P = 0.000). Univariate analysis showed that the characteristics with the prognostic significance for survival were tumor stage, lymph node metastasis, distant metastasis, histological grade and the expression of PD-ECGF. Multivariate analysis showed that tumor stage, histological grade and the expression of PD-ECGF were independent prognostic factors (OR: 17.971, 9.702, 6.790, 95%CI: 3.010 - 107.290, 1.835 - 51.305, 1.156 - 39.894). The expression of PD-ECGF may play an important role in the development and invasion of renal cell carcinoma. An elevated level of PD-ECGF is probably correlated with the prognosis of renal cell carcinoma.

(PDF emailed within 1 workday: $29.90)

Accession: 053146681

Download citation: RISBibTeXText

PMID: 22340655


Related references

The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 98(4): 730-736, 2003

Clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in gastric carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 61, 1996

Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urological Research 29(1): 7-12, 2001

Significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in carcinoma of the papilla of Vater. Japanese Journal of Cancer Research 91(3): 331-336, 2000

Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus. Hepato-Gastroenterology 46(26): 944-951, 1999

Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. British Journal Of Cancer. 68(4): 708-711, 1993

The effect of different fluoropyrimidines with or without a thymidine phosphorylase inhibitor on the expression of platelet derived endothelial cell growth factor/thymidine phosphorylase. Proceedings of the American Association for Cancer Research Annual Meeting 43: 966, 2002

Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. International Journal of Urology 8(9): 478-482, 2001

Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. British Journal of Cancer 73(8): 884-888, 1996

Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Research 58(7): 1551-1557, 1998

Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma. Journal of Urology 167(1): 347-351, 2002

Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Letters 108(2): 281-290, 1996

Regulation of expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 265, 1997

Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. Journal of Hepatology 29(2): 290-299, 1998

Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro. Oncology Reports 10(4): 967-971, 2003